CLINICAL_TRIALS
trial_result
· 2021-04-01
Clinical Trial Update: A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC [Phase 3]
Summary
Phase 3 trial comparing lorlatinib versus crizotinib in first-line ALK-positive non-small cell lung cancer; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-04-01